Barclays PLC restated their hold rating on shares of Mazor Robotics Ltd. (NASDAQ:MZOR) in a report released on Wednesday morning. Barclays PLC currently has a $34.00 price target on the medical instruments supplier’s stock.
A number of other analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a hold rating on shares of Mazor Robotics in a report on Wednesday, August 30th. Ladenburg Thalmann Financial Services set a $54.00 price target on shares of Mazor Robotics and gave the stock a buy rating in a report on Wednesday, August 30th. Finally, Zacks Investment Research downgraded shares of Mazor Robotics from a hold rating to a sell rating in a report on Tuesday, July 18th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company’s stock. Mazor Robotics currently has a consensus rating of Hold and a consensus price target of $37.67.
Shares of Mazor Robotics (NASDAQ:MZOR) opened at 54.07 on Wednesday. The firm’s market cap is $1.30 billion. Mazor Robotics has a 12-month low of $20.19 and a 12-month high of $55.66. The stock’s 50 day moving average is $48.11 and its 200 day moving average is $39.48.
Mazor Robotics (NASDAQ:MZOR) last issued its quarterly earnings results on Tuesday, August 1st. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.09. Mazor Robotics had a negative net margin of 37.66% and a negative return on equity of 28.51%. The company had revenue of $15.46 million during the quarter, compared to the consensus estimate of $15.38 million. During the same quarter in the prior year, the firm posted ($0.09) EPS. The firm’s quarterly revenue was up 86.7% on a year-over-year basis. Equities analysts expect that Mazor Robotics will post ($0.77) earnings per share for the current year.
A number of large investors have recently modified their holdings of MZOR. Wells Fargo & Company MN lifted its stake in Mazor Robotics by 46.3% in the 1st quarter. Wells Fargo & Company MN now owns 40,958 shares of the medical instruments supplier’s stock valued at $1,220,000 after purchasing an additional 12,959 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Mazor Robotics by 398.5% in the 1st quarter. JPMorgan Chase & Co. now owns 6,979 shares of the medical instruments supplier’s stock valued at $208,000 after purchasing an additional 5,579 shares during the last quarter. Credit Agricole S A bought a new position in Mazor Robotics in the 1st quarter valued at approximately $3,929,000. Menta Capital LLC bought a new position in Mazor Robotics in the 1st quarter valued at approximately $815,000. Finally, UBS Group AG lifted its stake in Mazor Robotics by 2.4% in the 1st quarter. UBS Group AG now owns 99,954 shares of the medical instruments supplier’s stock valued at $2,976,000 after purchasing an additional 2,379 shares during the last quarter. 25.92% of the stock is owned by institutional investors and hedge funds.
Mazor Robotics Company Profile
Mazor Robotics Ltd is an Israel-based medical device company that develops and markets surgical guidance systems and complementary products. It develops computerized and imaging-based systems in the field of spine surgery. Its products include: Renaissance Surgical Guidance System, which enables surgeons to advance from freehand surgical procedures to guided procedures, as well as Food and Drug Administration (FDA)-cleared and European Conformity (CE)-marked Renaissance System, used in spine surgeries, whether open or minimally invasive, for a number of clinical indications.